Enanta Hopes To Succeed In RSV With N-Protein Inhibition Approach
Enanta's N-protein inhibitor EDP-938 hit a pair of endpoints in a Phase IIa challenge study, but real-world testing may be a higher hurdle. The company believes its therapeutic approach is more effective than fusion protein prophylactic approaches.
You may also be interested in...
Enanta hoped its Phase II study would indicate a better efficacy and/or tolerability profile for EDP-305 compared to other FXR agonists for NASH, including Intercept’s OCA. Despite the inconclusive data, it plans a longer Phase IIb study.
Johnson & Johnson has written off a further $700m against the RSV asset that it obtained with its $1.75bn purchase of Alios.
Novavax’s shares plunged 67% on news that its Phase III trial for RSV had failed, but are there signs of life for the product?